Notably, LXR activation did alter function in CD4 + T-cells from RRMS patients demonstrated by significantly reduced intracellular IL-17A expression, reduced proliferation (Ki67), and increased IL-4 production in (Fig. 5C and D), as we observed previously in HCs [8], although interferon-γ production was unaffected. This evidence concerns the gene IL17A and relapsing-remitting multiple sclerosis.